Jiuzhitang Past Earnings Performance
Past criteria checks 3/6
Jiuzhitang has been growing earnings at an average annual rate of 5.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 4.1% per year. Jiuzhitang's return on equity is 6.6%, and it has net margins of 9.4%.
Key information
5.5%
Earnings growth rate
5.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -4.1% |
| Return on equity | 6.6% |
| Net Margin | 9.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Jiuzhitang Co., Ltd.'s (SZSE:000989) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 14
Weak Statutory Earnings May Not Tell The Whole Story For Jiuzhitang (SZSE:000989)
Nov 07Investors Aren't Buying Jiuzhitang Co., Ltd.'s (SZSE:000989) Earnings
Sep 30Jiuzhitang (SZSE:000989) Seems To Use Debt Rather Sparingly
Jun 26Revenue & Expenses Breakdown
How Jiuzhitang makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,654 | 249 | 1,170 | 152 |
| 30 Jun 24 | 2,822 | 257 | 1,241 | 150 |
| 31 Mar 24 | 2,712 | 238 | 1,201 | 150 |
| 31 Dec 23 | 2,961 | 297 | 1,318 | 145 |
| 30 Sep 23 | 2,940 | 255 | 1,314 | 145 |
| 30 Jun 23 | 2,963 | 234 | 1,352 | 152 |
| 31 Mar 23 | 2,926 | 397 | 1,327 | 147 |
| 01 Jan 23 | 3,033 | 358 | 1,357 | 142 |
| 30 Sep 22 | 3,256 | 392 | 1,382 | 127 |
| 30 Jun 22 | 3,595 | 420 | 1,540 | 119 |
| 31 Mar 22 | 3,835 | 287 | 1,651 | 111 |
| 01 Jan 22 | 3,784 | 271 | 1,677 | 118 |
| 30 Sep 21 | 3,890 | 315 | 1,739 | 116 |
| 30 Jun 21 | 3,805 | 295 | 1,689 | 123 |
| 31 Mar 21 | 3,813 | 291 | 1,693 | 121 |
| 31 Dec 20 | 3,560 | 272 | 1,570 | 113 |
| 30 Sep 20 | 3,493 | 231 | 1,596 | 110 |
| 30 Jun 20 | 3,328 | 213 | 1,530 | 99 |
| 31 Mar 20 | 3,144 | 201 | 1,463 | 94 |
| 31 Dec 19 | 3,184 | 192 | 1,519 | 102 |
| 30 Sep 19 | 2,966 | 191 | 1,387 | 105 |
| 30 Jun 19 | 3,050 | 186 | 1,487 | 107 |
| 31 Mar 19 | 3,256 | 275 | 1,645 | 96 |
| 31 Dec 18 | 3,162 | 336 | 1,518 | 85 |
| 30 Sep 18 | 3,634 | 541 | 1,747 | 81 |
| 30 Jun 18 | 3,860 | 686 | 1,821 | 91 |
| 31 Mar 18 | 3,991 | 731 | 1,872 | 91 |
| 31 Dec 17 | 3,837 | 721 | 1,769 | 70 |
| 30 Sep 17 | 3,495 | 703 | 1,485 | 40 |
| 30 Jun 17 | 3,190 | 710 | 1,222 | 0 |
| 31 Mar 17 | 2,761 | 654 | 909 | 0 |
| 31 Dec 16 | 2,674 | 652 | 866 | 0 |
| 30 Sep 16 | 2,145 | 572 | 678 | 0 |
| 30 Jun 16 | 1,723 | 554 | 479 | 0 |
| 31 Mar 16 | 1,271 | 490 | 289 | 0 |
| 31 Dec 15 | 872 | 471 | 138 | 0 |
| 31 Dec 14 | 798 | 403 | 148 | 0 |
| 31 Dec 13 | 704 | 364 | 124 | 0 |
Quality Earnings: 000989 has high quality earnings.
Growing Profit Margin: 000989's current net profit margins (9.4%) are higher than last year (8.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000989's earnings have grown by 5.5% per year over the past 5 years.
Accelerating Growth: 000989's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000989 had negative earnings growth (-2.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 000989's Return on Equity (6.6%) is considered low.